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Abstract
Background: Circulating tumor cell (CTC)-filtration methods capture high numbers of CTCs in non-small-cell lung
cancer (NSCLC) and metastatic prostate cancer (mPCa) patients, and hold promise as a non-invasive technique for
treatment selection and disease monitoring. However filters have drawbacks that make the automation of microscopy
challenging. We report the semi-automated microscopy method we developed to analyze filtration-enriched CTCs
from NSCLC and mPCa patients.
Methods: Spiked cell lines in normal blood and CTCs were enriched by ISET (isolation by size of epithelial tumor cells).
Fluorescent staining was carried out using epithelial (pan-cytokeratins, EpCAM), mesenchymal (vimentin, N-cadherin),
leukocyte (CD45) markers and DAPI. Cytomorphological staining was carried out with Mayer-Hemalun or Diff-Quik.
ALK-, ROS1-, ERG-rearrangement were detected by filter-adapted-FISH (FA-FISH). Microscopy was carried out using an
Ariol scanner.
Results: Two combined assays were developed. The first assay sequentially combined four-color fluorescent staining,
scanning, automated selection of CD45− cells, cytomorphological staining, then scanning and analysis of CD45− cell
phenotypical and cytomorphological characteristics. CD45− cell selection was based on DAPI and CD45 intensity,
and a nuclear area >55 μm2. The second assay sequentially combined fluorescent staining, automated selection
of CD45− cells, FISH scanning on CD45− cells, then analysis of CD45− cell FISH signals. Specific scanning parameters
were developed to deal with the uneven surface of filters and CTC characteristics. Thirty z-stacks spaced 0.6 μm apart
were defined as the optimal setting, scanning 82 %, 91 %, and 95 % of CTCs in ALK-, ROS1-, and ERG-rearranged
patients respectively. A multi-exposure protocol consisting of three separate exposure times for green and red
fluorochromes was optimized to analyze the intensity, size and thickness of FISH signals.
Conclusions: The semi-automated microscopy method reported here increases the feasibility and reliability of
filtration-enriched CTC assays and can help progress towards their validation and translation to the clinic.
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Background
Circulating tumor cells (CTCs) captured from blood as a
liquid biopsy are currently a very active and promising
area in translational cancer research [1]. CTCs are very
rare cells – occurring at rates as low as one cell per 106
or 107 leukocytes – which detach from a primary tumor
or metastatic site, circulate in the peripheral blood and
may colonize secondary sites to form metastasis [2, 3].
To date, identification and characterization of CTCs has
been hampered by their rarity, their phenotypical and
genetic heterogeneity and the technical limitation of
current assays [4]. As a consequence, CTC detection
methods commonly rely on two steps, a first enrichment
step based on either CTC phenotypical or physical prop-
erties, and a secondary step of detection to increase the
sensitivity of the assay. The semi-automated CellSearch
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platform (Janssen Diagnostics, LLC, Raritan, USA) en-
riches CTC candidates through ferromagnetic beads
coated with epithelial cell adhesion molecule (EpCAM)
specific antibody and defines CTCs according to the
presence of cytokeratins (CK8, CK18 and CK19) and the
absence of the common leukocyte antigen CD45 [5]. In
prospective multicenter studies in metastatic breast,
prostate (mPCa) and colon cancers [6–8], CTC levels
using this platform were shown to have prognostic sig-
nificance, and extensive analytical validation and clinical
qualification led the U.S. Food and Drug Administration
(FDA) to approve CellSearch as an aid to prognosis in
these tumors. In non-small-cell lung cancer (NSCLC),
CTC levels were also reported to have a prognostic
value, but the number of CTCs caught by the CellSearch
remains low in this tumor type even in patients with
metastatic advanced disease [9]. The potential reason for
this is that CTCs have lost epithelial features, expressing
markers of the epithelial-mesenchymal transition (EMT)
which can be missed by the CellSearch [10–12]. In
addition to prognostic utility, CTCs are currently exten-
sively studied to detect predictive biomarkers and screen
eligible patients for targeted therapies [13–20]. Moreover
analyses performed on CTCs could be repeated at differ-
ent time-points during treatment to monitor response
and guide therapeutic decisions. Performing molecular
analysis in CTCs analyzed by the CellSearch is relatively
challenging in cancers such as NSCLC due to the low
numbers of CTCs captured and the processing condi-
tions of the system.
The limitations of the CellSearch and other antibody-
based capture methods have stimulated the development of
other technologies for CTC enrichment and detection [4].
An alternative approach consisting of distinguishing CTCs
from normal hematopoietic cells according to size is being
actively explored. Several filter devices have been described
including ISET (ISET, isolation by size of epithelial tumor
cells, Rarecells, Paris, France) [21–23], ScreenCell [24],
the Accucyte system [25], CellSieve [26], the Portable
Filter-based Microdevice [27], VyCAP [28], the Siemens
prototype [29] and the Parsortix system [30]; allowing
identification of CTCs according to cytomorphological,
phenotypical or molecular characteristics. Ours and
other groups have reported that higher numbers of
CTCs are captured in cancers such as NSCLC and
mPCa using a filtration system compared to CellSearch
[10, 26, 31, 32]. CTCs expressing mesenchymal and epi-
thelial markers were reported in NSCLC, mPCa and
breast cancer patients using filtration enrichment [11, 12,
26, 33, 34] and CTCs enriched by ISET were reported to
have a prognostic value in resected NSCLC patients [31].
By capturing CTCs independent of surface-marker
expression, filtration methods may offer a significant
advantage for covering the phenotypic and genetic
heterogeneity of CTCs, and identification of predictive
markers. We and another group reported the detection
of ALK-rearrangement in CTCs ISET-enriched by filtration
in NSCLC patients with an ALK-rearranged tumor
[17, 18, 35] as well ROS1-rearrangement in CTCs from
NSCLC patients with an ROS1-rearranged tumor [20].
While offering important advantages such as sensitivity
of CTC capture and flexibility for CTC characterization
following filtration, filtration systems have drawbacks.
One problem is that it is difficult to design a filter mem-
brane which sits entirely flat, regardless of the material
used: virtually all filter membranes developed today are
not microscopically flat. Another is that pores inevitably
retain white blood cell debris and fluorescence signals
which disturb microscopy analysis, thus cells placed on
pores are frequently difficult to analyze. These two prob-
lems make the automation of microscopy challenging to
implement. Given these difficulties the microscopy ana-
lysis of CTCs enriched on filters remains manual, time-
consuming due to the high numbers of white blood cells
present on filters, and highly operator-dependent.
Although automation is an essential step for filtration-
enriched CTC assays to progress to the clinic, there is
today no published method reporting the semi-
automation of microscopy and image analysis of filtration-
enriched CTCs.
Here we report the semi-automated method estab-
lished to analyze filtration-enriched CTCs from NSCLC
and mPCa according to two combined assays i.e (i)
fluorescent staining and high-resolution cytomorphol-
ogy; (ii) fluorescent staining and fluorescent in situ
hybridization (FISH). The first method aims to identify
CTCs according to both phenotypical and cytomorpho-
logical parameters and includes the establishment of
scanning parameters for selecting and creating an image
gallery of CD45− cells, and characterizing CTCs. The
second relies on the detection of molecular biomarkers
by establishing FISH scanning parameters (z-stacking,
step i.e. distance between two z-stacks, exposure time)




NSCLC and mPCa patients were recruited at the
Gustave Roussy, Paris, France. Informed written consent
for blood sample collection was obtained from all pa-
tients (IDRCB2008-A00585-50). The study was approved
by local institutional board and ethics committees. Blood
was collected into EDTA tubes.
Blood sample collection and enrichment of CTCs by ISET
CTC enrichment by the ISET filtration system (RareCells,
Paris, France) was carried out according to the
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manufacturer’s protocol, as previously reported [10, 11].
To preserve cell integrity, the filtration pressure was opti-
mized to -7 kPa. After processing, filters were dried,
wrapped in an aluminum sheet and stored frozen in plas-
tic bag containing a silica gel desiccant at -20 °C until use.
Fluorescent staining of filtration-enriched CTCs
ISET filters are composed of 10 spots. Each spot (corre-
sponding to filtration of 1 mL blood) was cut out for in-
dependent analysis. Filters were thawed and individual
spots were immobilized on glass slides using adhesive
ribbon. A ‘snick’ was made on each spot to allow the
precise relocation of cells between fluorescent staining
and cytomorphological staining. After rehydratation in
TBS 1X (Thermo Fisher Scientific Inc., Waltham, MA,
USA), cell permeabilization was carried out by incubat-
ing filters for 7 min at room temperature in TBS 1X-
Triton X-100 0.2 % (Roche, Sigma-Aldrich Co. LLC.,
Saint-Louis, MO, USA). After a wash with TBS 1X, sat-
uration was carried out by incubating filters for 25 min
at room temperature in TBS 1X-normal goat serum 5 %
(Thermo Fisher Scientific Inc.). Epithelial markers were
employed in the “green” channel including mouse anti-
pancytokeratin monoclonal antibodies (clone A45-B/B3,
AS Diagnostik, Hueckeswagen, Germany; clone C11,
Novus Biological, Littleton, CO, USA; clone KL1, Beckman
Coulter, Brea, CA, USA; clone OV-TL 12/30, Dako, Les
Ulis, France) directly conjugated to Alexa Fluor (AF) 488
using the Zenon Mouse IgG Labeling Kit (Thermo Fisher
Scientific Inc.) and EpCAM/CD326 AF488 (clone VU1D9,
Novus Biological). An anti-vimentin (clone V9, Santa Cruz
Biotechnology, Heidelberg, Germany) or an anti-N-
cadherin (clone 32/N-Cadherin, BD Biosciences, Franklin
Lakes, NJ, USA) conjugated in AF546 and allophycocyanin
(APC)-conjugated anti-CD45 (clone HI30, BD Biosciences)
were used. Antibodies incubation was carried out 25 min in
a humidity dark chamber. After two washes with TBS 1X-
Tween20 0.05 % (Dako) and TBS 1X, 4′,6-diamidino-2-
phenylindole (DAPI) or Hoechst 33342 (Sigma-Aldrich)
was added for 10 min. ISET spots were mounted between
slide and coverslip using Ibidi mounting medium (Biovalley,
Nanterre, France). Slides were stored at +4 °C until
scanning.
Cytomorphological staining of filtration-enriched CTCs
After fluorescence scanning, the coverslip and the
mounting medium were removed using a wash of PBS
1X, filters were stained with Mayer Hemalun (RAL
Diagnostics, Martillac, France) at room temperature for
30 min or with Diff-Quik (Siemens Healthcare diagn.,
Munich, Germany) according to the manufacturer's
protocol. ISET spots were mounted using Ibidi mounting
medium and stored at +4 °C until scanning.
Scanning and image analysis of combined fluorescent and
cytomorphological staining in filtration-enriched CTCs
Scanning and image analysis were carried out using an
Ariol scanning system (Leica Biosystems Richmond Inc.,
Richmond, IL, USA) including a Leica DM6000 B micro-
scope with multibay stages (MB 8). Single interference
filter sets for blue (DAPI), green (FITC), red (Texas Red)
and dark red (Cy5) filters were used. Calibrations were
performed using the Ariol Scan application 4.0.1.5 (Leica
Biosystems Richmond Inc.). After delineation of the
scanning area (i.e. one entire ISET spot) at ×5 magnifica-
tion, gain was set at maximum (255) to eliminate risk of
fluorochrome bleaching. Exposure time was calibrated
for each channel at ×20 magnification. Using only one
parameter (i.e. exposure time for adjusting fluorochrome
exposure) allowed to compare settings between scans
done at different times or by different users. Exposure
time for epithelial markers was adjusted to have a very
low signal on CD45+ cells (at limit of the background
noise) while the exposure time of the mesenchymal
marker was set to have a saturated signal on CD45+ cells
which are known to be strongly positive. Offset was cali-
brated as high as possible in the DAPI channel to
individualize at best nucleus. Selection of CD45− from
CD45+ elements was carried out in real time by the
Ariol scanning system. The fluorescence scan takes
~1 h30 for one ISET spot. For cytomorphological stain-
ing scanning a pre-scan of the whole spot was per-
formed at ×5 in the brightfield channel, the snick being
used to precisely relocate cells. The cytomorphological
staining scan takes ~45 min at x 20 magnification. All
images were analyzed with the Ariol Review application
4.0.1.5 (Leica Biosystems Richmond Inc.).
Combination of fluorescent staining and FA-FISH of
filtration-enriched CTCs
Filters were thawed and individual spots were immobi-
lized on glass slides using adhesive ribbon. A snick was
made on each spot for precise CD45− cell relocation for
filter-adapted-FISH (FA-FISH) scanning. After rehydra-
tation in TBS 1X (Dako), filters were incubated for
5 min at 98 °C in TBS 1X-EDTA (Dako) and then
30 min in TBS 1X-normal mouse serum 5 % (Thermo
Fisher Scientific Inc.). Fluorescent staining was per-
formed overnight with anti-CD45 in a dark humidity
chamber. After three washes with TBS 1X-Tween20
0.05 % followed by TBS 1X, nuclear staining was per-
formed using DAPI for 15 min. For FA-FISH, filters were
then washed with TBS 1X-Tween 20 0.05 %, incubated for
30 min at room temperature in methanol:acetic acid (9:1)
solution and then digested at 37 °C with a pepsin
(Sigma-Aldrich) solution at 10 % in 0.01 N HCL.
After washing with PBS 1X, filters were fixed at room
temperature in formaldehyde solution (Sigma-Aldrich)
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and dehydrated in successive baths containing increasing
concentrations of ethanol (VWR International, Radnor,
PA, USA). FA-FISH experiments were performed using
several probes according to the manufacturer’s protocol:
the Vysis LSI ALK Break Apart Rearrangement Probe Kit
(Abbott Molecular Inc., Des Plaines, IL, USA); the Vysis
6q22 ROS1 Break Apart FISH probe RUO Kit (Abbott
Molecular Inc.); the ZytoLight SPEC RET Dual Color
Break (ZytoVision GmbH, Bremerhaven, Germany); the
Vysis EGFR/CEP7 FISH Probe Kit (Abbott Molecular
Inc.); the Cytocell c-met amplification Probe Kit (Cytocell
Ltd., Cambridge, UK); the ZytoLight SPEC FGFR1/CEN8
Dual Color Probe (ZytoVision GmbH); the FIP1L1-
PDGFRA FISH DNA Probe (Dako) with the TelVysion 4q
(Abbott Molecular Inc.); the Vysis AR amplification Probe
Kit (Abott Molecular Inc.); the Kreatech ERG Break Apart
Rearrangement Probe Kit (Kreatech Diagnostics,
Amsterdam, Netherlands). After hybridization, filters were
washed in stringent wash buffer 1X (Dako) and wash buf-
fer 1X (Dako), then dehydrated again in successive ethanol
solutions. Filters were finally mounted using DAPI mount-
ing medium (Dako). All FISH probes were optimized for
FA-FISH using cancer cell lines spiked in normal blood
and filtered by ISET (Additional file 1: Figure S1).
Scanning and image analysis of combined fluorescent
staining and FA-FISH in filtration-enriched CTCs
Scanning and image analysis of fluorescent staining were
carried out as described above. For scanning FA-FISH, a
pre-scan of the whole ISET spot was first performed
at ×5 magnification in the DAPI channel to precisely re-
locate cells. Thanks to the snick made on the spot, the
fluorescence and the FA-FISH scans were linked. A scan
pass in the DAPI channel at ×10 magnification was de-
veloped for adjustment of focus and FISH capture was
performed at ×63 magnification in the small regions
containing CD45− cells. The z-stack number, step, gain,
offset and exposure time (ranging from 5 to 100 ms)
were calibrated at ×63 magnification. The Ariol scanning
system adjusted the focus on DAPI every frame. All im-
ages were analyzed with the Ariol Review application
4.0.1.5. To determine the best number of z-stacks, filter
enriched-CTCs from patients with ALK-, ROS1- and
ERG-rearranged tumors were scanned six times from 5
z-stacks to 30 z-stacks. For the best step determination,
filter enriched-CTC were scanned four times with steps
ranging from 0.5 to 0.8 μm. No bleaching was observed.
Cell lines
The NCI-H2228, HCC78, NCI-H661, A549, H1975 and
LNCaP cell lines were cultured in RPMI medium 1640
(Thermo Fisher Scientific Inc.) and TPC1, A-431, MB-
MDA-134, Res259, VCaP in DMEM medium (Thermo
Fisher Scientific Inc.) supplemented with 10 % fetal
bovine serum and maintained in a humidified incuba-
tor in 5 % CO2 at 37 °C. Cell lines were spiked at
various dilutions into blood from healthy donors fil-
tered on ISET, as done for patient samples.
Results
Semi-automated microscopy method to identify filtration-
enriched CTCs by combined phenotypical and
cytomorphological analysis
CTCs are most often identified phenotypically through
the detection of epithelial markers by immunofluorescent
staining. Filtration-enriched CTCs may also be identified
according to true cytomorphological criteria such as nu-
cleus size (compared with the size of the filter pores
(8 μm) corresponding to the internal control) and irregu-
larity of the nuclear membrane, the presence of a visible
cytoplasm and a high nuclear-to-cytoplasmic ratio [10, 31,
36]. To further characterize filtration-enriched CTCs, we
established a method where CTCs were identified by com-
bining phenotypical (immunofluorescent staining) and
cytomorphological characterization, and report here the
semi-automated scanning and image analysis method de-
veloped to analyze filters. Using cancer cell lines spiked in
normal blood and filtered by ISET, we developed a multi-
step process where filters were (i) treated by four-color
fluorescent staining, (ii) scanned using an Ariol scanning
system and automatically analyzed to select CD45− from
CD45+ cells, (iii) treated by a cytomorphological dye, (iv)
scanned and analyzed again using the Ariol scanning sys-
tem to gather for cells of interest phenotypical and cyto-
morphological images, and cell characteristics (Fig. 1a). To
identify CTCs potentially undergoing EMT, four-color
fluorescent staining was carried out using epithelial (pan-
cytokeratins, EpCAM), mesenchymal (vimentin or N-
cadherin) markers, CD45 and nuclear staining (DAPI or
Hoechst 33342).
Three scanning parameters including gain and exposure
time – which operate on fluorochrome intensity – and
offset – which operates on the fluorescent background of
the membrane – were critical for the automated selection
of CD45− cells. CD45 exposure time was systematically
adjusted as high as possible to optimally discriminate
CD45− and CD45+ cells (Fig. 2a). The exposure time of
epithelial and mesenchymal markers was adjusted to de-
tect low marker expression as expected in CTCs undergo-
ing EMT (Fig. 2a). Offset calibration in the DAPI channel
was critical to fully demarcate nuclei and automatically se-
lect individual CD45− from CD45+ cells. To adjust for the
uneven surface of the membrane, the focus was deter-
mined before scanning using nine focus points across the
filter, then readjusted every frame during scanning (~350
times). Using this scanning method, the total number of
cells (mostly CD45+) counted per 1 mL ISET spot was
highly variable, ranging from 6000 to 20000. The
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automated selection of CD45− cells was based on three
criteria: (i) intensity of DAPI, (ii) intensity of CD45, (iii) a
nuclear area superior to 55 μm2 (an area of 50 μm2
corresponds to a pore of 8 μm diameter). In order to
select clusters, and especially mixed clusters which
contain both CTCs and CD45+ cells, a nuclear area su-
perior to 150 μm2 (equivalent of three pores) was
added as a fourth criteria, and the CD45 intensity was
not considered in this situation. All selected DAPI+/CD45−
elements (usually ranging from 10 to 150 elements
per 1 mL ISET spot) were reviewed manually and
classified according to their phenotype and nucleus
size. Eight categories were established including exclu-
sively epithelial cells (E+/M−), cells in EMT (E+/M+),
mesenchymal cells (E−/M+), cells with no markers and
a nucleus diameter superior to 16 μm (E−/M− > 2 pores),
Fig. 1 Experimental process for the two combined assays. a Schematic workflow for the identification of filtration-enriched CTCs by combined
fluorescent staining and high-resolution cytomorphology. b Schematic workflow for detection of molecular biomarkers in filtration-enriched CTCs
by combined fluorescent staining and fluorescent in situ hybridization (FISH)
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cells with no markers and a nucleus diameter inferior to
16 μm (E−/M− < 2 pores), CTC clusters (number of
CTCs ≥ 4), mixed clusters (number of CD45+ cells
and CTCs ≥ 4), and microclusters (number of CD45−
and/or CTC = 3). The characteristics of each selected
element such as cell area and fluorescence intensities
Fig. 2 Scanning and image gallery of A459 cells spiked in normal blood and filtered by ISET. a Images of the whole ISET filter (left panel). Grey
windows and right panels show DAPI/CD45 APC and DAPI/CD45 APC/Epithelial markers AF488/Mesenchymal markers AF546 channels. b Zoom
in images for DAPI/CD45 APC/Epithelial markers AF488/Mesenchymal markers AF546 channels. The image gallery of A549 cells and cell characteristics
are shown. Cell categories after automated selection of CD45− cells and manual review of images are shown. The white arrow indicates an A549 cell,
orange arrows indicate CD45+ cell into pores, the blue arrow a CD45+ cell outside a pore. Abbreviations: Avg_Int, DAPI average intensity; Avg_Int_Bg,
background average intensity, Sec_Avg_Int, CD45 average intensity; Ter_Avg_Int, AF488 average intensity; Quat_Avg_Int, AF546 average intensity
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Fig. 3 Examples of isolated CTCs (E+/M−, E+/M+, E−/M+, E−/M− > 2 pores respectively) identified by combined fluorescent staining and high-resolution
cytomorphology in representative a NSCLC and b mPCa patients. c Examples of CTC clusters, mixed clusters and microclusters respectively in NSCLC
and/or mPCa patients. Scale: white bars = 10 μm
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were detailed in an image gallery. An example of
A549 cancer cells spiked in normal blood and
treated as mentioned above is shown in Fig. 2.
High-resolution cytomorphology was carried out by
staining filters with either Mayer Hemalun or Diff-Quik,
and scanning in brightfield. Cytomorphological images
were precisely relocated within CD45− cell subpopulations
using the Ariol scanning system and validated by an expe-
rienced cytopathologist (PV). Five criteria were used to de-
fine an epithelial CTC including i) presence of a well-
defined and non-damaged nucleus inside the cytoplasm,
ii) absence of CD45 expression, iii) expression of epithelial
markers, iv) nuclear size superior to 1.5 pore diameter (i.e.
12 μm), v) presence of a well-defined cytoplasm. Examples
of isolated CTCs from NSCLC and mPCa patients identi-
fied using these five criteria and harboring only epithelial
markers or both epithelial and mesenchymal markers are
shown in Fig. 3 (a and b). In the absence of epithelial
marker expression, CTCs were defined as cells presenting
all the following cytomorphological criteria: i) nucleus size
superior to two pores (i.e. ≥ 16 μm), ii) nucleus irregular-
ity, iii) high nuclear-to-cytoplasmic ratio. CTCs with no
detectable epithelial marker expression but cytomor-
phological characteristics of CTCs were consistently
detected in both NSCLC and mPCa patients as shown
in Fig. 3 (a and b). Examples of clusters from NSCLC
and/or mPCa patients are shown in Fig. 3c.
Semi-automated microscopy method to identify filtration-
enriched CTCs by combined phenotypical and FA-FISH
analysis
We previously reported a method for FA-FISH on ISET
filters, optimized to decrease non-specific fluorescent
probe binding to the filter membrane and confer high cell
recovery [18, 20]. Scanning software is commonly able to
analyze around 100 cells per tumor sample by FISH, and
it was therefore not possible to scan all cells (6000 to
20,000, as mentioned above) present on a 1 mL ISET spot.
To decrease the numbers of cells to scan, we limited the
FISH analysis to CD45− cells: this option provided the
Table 1 FISH spots detected per CTC in a patient with an ALK-rearranged tumor depending on the number of z-stacks
CTC ID Number of FISH spots
5 z-stacks 10 z-stacks 15 z-stacks 20 z-stacks 25 z-stacks 30 z-stacks
1 n.ia 9 9 13 10 18
2 3 8 6 16 15 16
3 n.ia 3 2 8 7 12
4 4 11 2 4 13 13
5 n.ia 5 6 8 8 17
6 n.ia 12 4 4 2 16
7 8 6 8 19 1 27
8 2 4 4 8 10 15
9 2 2 3 13 7 16
10 n.ia 22 6 14 17 27
11 n.ia 4 8 8 10 16
12 1 10 6 16 12 16
13 1 4 2 16 2 3
14 n.ia 6 9 14 14 14
15 2 4 n.ia 4 4 16
16 1 10 8 2 7 16
17 n.ia 6 9 8 20 9
18 6 7 7 16 14 16
19 6 7 n.ia 10 12 18
20 3 8 6 6 8 18
21 1 3 9 6 8 8
22 2 5 6 n.i.a 14 8
%b 0 % 0 % 4 % 23 % 18 % 82 %
Abbreviations: ALK anaplastic lymphoma kinase gene; CTC circulating tumor cell; FISH fluorescence in situ hybridization; n.i. non-interpretable
aNumber of FISH spots is uncountable due to non-optimal focus in the DAPI channel
bPercentage of cases where a higher number of FISH spots were observed
The numbers in bold correspond to the highest number of spots for this CTC
Pailler et al. BMC Cancer  (2016) 16:477 Page 8 of 15
additional advantage of excluding CD45+ subpopulations
which could occasionally harbor unspecific FISH re-
arrangement signals when damaged (data not shown). We
established a second multi-step process where filters were
(i) treated by fluorescent staining, (ii) scanned on the Ariol
scanning system and analyzed automatically to locate
CD45− cells as described above, (iii) treated by FA-FISH,
(iv) scanned in the small regions containing the CD45−
cells, (v) and analyzed for detection, interpretation and
validation of FISH signals within CD45− cells (Fig. 1b).
FISH scanning in tumor specimens depends on three
parameters: z-stacking (usually ranging from 7 to 11
stacks), the step i.e. the distance between z-stacks (usu-
ally 0.6 μm or 0.7 μm), and the exposure time of red and
green fluorochromes. FISH scanning of filter enriched-
CTCs must take into consideration two particular char-
acteristics of CTCs and filters: first, CTCs are not cut as
tissue sections and may have a large nucleus (superior to
30 μm in diameter). These characteristics add to the un-
even surface of the filter and strongly influence the
above three parameters. Second, CTCs are frequently lo-
cated in pores which contain DAPI positive debris and
fluorescent signals, rendering their analysis challenging.
We first determined the best number of z-stacks to scan
filter enriched-CTCs from patients with an ALK-rear-
ranged tumor. Six independent scans of the same filters
were performed with an increasing number of z-stacks
ranging from 5 to 30, at an arbitrary step of 0.6 μm.
Thirty was the maximum z-stack number tolerated by
the scanner. As shown in Table 1, 30 z-stacks was the
optimal setting to scan CTC FISH spots (82 % detec-
tion rate) in an patient with ALK-rearranged tumor,
while fewer spots were detected at lower numbers of
z-stacks. Thirty z-stacks were also optimal to scan
CTC FISH spots in patients with a ROS1-rearranged
tumor (91 % detection rate) (Table 2). In a patient
with ERG-rearranged tumor, 30 stacks also allowed a
95 % detection rate of CTC FISH spots (Table 3).
Thirty z-stacks were therefore established as the opti-
mal setting for scanning filter-enriched CTCs.
We next examined the influence of the step on the
number of FISH spots. Scanning of the same filters was
performed with an increasing step, ranging from 0.5 μm
to 0.8 μm. As shown in a patient with ALK-rearranged
tumor (Table 4), a maximal number of FISH spots was
detected at a step of 0.6 μm (92 % detection rate). This
was confirmed in filters from patients with ROS1- and
ERG-rearranged tumors (Additional file 2: Table S1 and
Additional file 3: Table S2).
The exposure time of red and green signals was observed
to strongly influence the intensity, size and thickness of
FISH spots. Because FISH signal intensities were highly
variable from one ISET filter region to another one, we de-
veloped a multi-exposure protocol to analyze FISH signals
consisting of three exposure times for both the green and
red fluorochromes (Fig. 4). Twenty-seven settings of expos-
ure time were in theory possible allowing for each candi-
date CTC the selection of the best setting. As shown in
Fig. 4a, the highest exposure was not systematically the best
setting, as thick signals can give a false idea of the distance
between two spots. To identify CTCs harboring abnormal
FISH patterns, signals present in DAPI+/CD45− cells were
systematically validated by an experienced cytogeneticist
(NA). Examples of filtration-enriched CTCs harboring
ALK-, ROS1-, RET-, or ERG-gene alterations from NSCLC
and mPCa are illustrated in Fig. 5.
Discussion
Here we reported the development of a semi-automated
microscopy method for analyzing filtration-enriched CTCs
using two combined assays. The first assay allowed
Table 2 FISH spots detected per CTC in a patient with a
ROS1-rearranged tumor depending on the number of z-stacks
CTC ID Number of FA-FISH spots
5 stacks 10 stacks 15 stacks 20 stacks 25 stacks 30 stacks
1 9 n.ia 6 14 14 30
2 4 10 10 10 10 10
3 12 22 18 28 28 28
4 3 2 n.ia 13 14 14
5 4 4 4 4 4 4
6 26 28 26 34 34 34
7 6 15 11 20 28 28
8 36 42 48 52 62 62
9 10 14 18 20 30 30
10 13 20 22 26 30 30
11 2 12 12 13 14 14
12 6 6 8 10 14 14
13 4 6 6 8 14 14
14 8 13 20 32 32 32
15 10 14 14 16 16 16
16 10 12 13 16 16 16
17 2 6 4 15 16 16
18 4 11 16 25 25 25
19 20 33 26 46 55 64
20 12 14 12 14 15 14
21 11 n.ia 20 24 28 28
22 10 12 12 20 19 12
%b 4 % 9 % 9 % 41 % 86 % 91 %
Abbreviations: CTC circulating tumor cell; FISH fluorescence in situ
hybridization; n.i. non-interpretable; ROS1 c-ros oncogene 1
aNumber of FISH spots is uncountable due to non-optimal focus in the
DAPI channel
bPercentage of cases where a higher number of FISH spots were observed
The numbers in bold correspond to the highest number of spots for this CTC
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identification of CTCs by combining four-color fluores-
cence to high-resolution cytomorphological analysis. The
microscopy method of this first assay included establish-
ment of scanning parameters, definition of criteria for cre-
ating an image gallery of CD45− cells, and definition of
criteria to identify CTCs among CD45− cells based on
both phenotypical and true cytomorphological character-
istics. The second process was developed to identify mo-
lecular biomarkers in CTCs by combining fluorescent
staining and FISH. After identification and location of
CD45− cells on filters as established in the first assay, the
method included the establishment of parameters for
scanning FA-FISH into filter regions containing CTC can-
didates, and the analysis of FISH using a multi-exposure
protocol for optimal definition of signals. These two assays
were possible due to the capacity of the Ariol scanning
system to perfectly relocate images i.e. images of fluores-
cence and cytomorphology, and images of fluorescence
and FA-FISH signals in CD45− cells.
In contrast to antibody-based immunomagnetic en-
richment, high numbers of CD45+ cells are retained by
most filtration systems [10, 26, 32, 37]. The automated
selection of CD45− cells greatly reduces the number of
cells to analyze (here approximately 100 cells instead of
6000 to 20000) thereby improving the feasibility of the
assay and the reliability of the results. CTCs were identi-
fied among selected CD45− cell candidates by examining
high-resolution images from both four-color fluores-
cence and cytomorphology. High-resolution cytomor-
phology is only possible when cells collected on filters
are intact and their morphology well preserved during
the filtration process. Although very time-consuming
given the number of spots to analyze and the high num-
ber of CD45+ cells retained per spot, ISET offers the ad-
vantage of preserving cellular integrity. In both NSCLC
and mPCa patients, we observed CTCs that were nega-
tive for epithelial and mesenchymal markers but were
validated as true CTCs by a cytopathologist (PV). One
Table 3 FISH spots detected per CTC in a patient with an ERG-rearranged tumor depending on the number of z-stacks
CTC ID Number of FA-FISH spots
5 z-stacks 10 z-stacks 15 z-stacks 20 z-stacks 25 z-stacks 30 z-stacks
1 5 9 2 10 16 22
2 23 32 22 32 33 36
3 4 12 6 15 16 16
4 11 20 10 24 30 32
5 10 6 12 16 14 16
6 26 14 2 30 31 45
7 34 4 2 39 59 59
8 15 4 4 27 31 31
9 14 8 2 31 33 34
10 6 2 16 26 26 31
11 2 2 4 15 16 22
12 14 32 2 60 58 61
13 13 0 20 28 28 28
14 10 10 12 35 32 35
15 17 10 10 56 53 65
16 16 6 8 28 30 32
17 6 6 10 14 15 16
18 5 14 2 14 14 20
19 8 4 6 16 26 31
20 30 20 26 52 52 44
21 4 16 6 12 18 27
22 7 n.ia 6 30 29 30
%b 0 % 0 % 0 % 23 % 23 % 95 %
Abbreviations: CTC circulating tumor cell; ERG v-ets avian erythroblastosis virus E26 oncogene homolog; FISH fluorescence in situ hybridization;
n.i. non-interpretable
aNumber of FISH spots is uncountable due to non-optimal focus in the DAPI channel
bPercentage of cases where a higher number of FISH spots were observed
The numbers in bold correspond to the highest number of spots for this CTC
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cannot completely exclude that CTCs undergoing EMT
and expressing a low level of epithelial and mesenchymal
markers may be missed by our immunofluorescent assay.
Furthermore as shown here, the level of both epithelial
and/or mesenchymal marker expression detected in ac-
tual filtration-enriched CTCs can be substantially lower
than that of spiked cell lines, a difference we also ob-
served using manual microscopy. Although we have no
evident explanation for this, the combination of four-
color fluorescence to high-resolution cytomorphology
contributes to a better characterization of such CTCs
and reliability of the results. Therefore by combining
phenotypic and cytomorphological data and high-
resolution images, the approach described here enables
us to better characterize CTCs as well as detect more
CTCs than with phenotypic analyses alone, further
highlighting the considerable phenotypic and cytomor-
phological heterogeneity of CTCs.
FISH analysis of tumor specimens for diagnostic test-
ing of biomarkers such as ALK- or ROS1-rearrangement
is in most cases still done manually by cytogeneticists.
Tumor cells are identifiable by their morphology and
the manual analysis offers the possibility to perform as
many stacks as necessary for capturing all FISH spots.
Manual FISH analysis of filters is laborious given the
number of CD45+ cells retained per filter. It may also
be a source of errors since it is well known by cytogen-
eticist that apoptotic CD45+ cells may harbor non-
specific break apart FISH signals. Given the size of
CTCs and the absence of an even filter surface, 30 z-
stacks spaced 0.6 μm apart were required to capture a
maximum of FISH spots and identify ALK-, ROS1- and
ERG-rearrangement in CTCs from NSCLC and mPCa
patients. Pre-analytical steps during ISET filtration were
found critical for the quality of FA-FISH and optimal
scanning, especially the possibility to filter at a very low
pressure enabling preservation of cell integrity. Unlike
tissue sections, standard scanning settings were unable
to capture all FISH spots present in filtration-enriched
CTCs. The multi-exposure protocol offering twenty-
seven exposure settings was therefore essential for opti-
mal capture and definition of FISH signals that were
systematically validated by an experienced cytogeneti-
cist (NA).
Multiple studies have highlighted the important
phenotypic and genetic heterogeneity of CTCs which
cannot be covered by a single CTC isolation technique.
Some of these studies have also shown the capacity of
filtration to enrich CTCs harboring distinct epithelial-to-
mesenchymal phenotypes, capturing higher numbers of
CTCs compared to antibody-based methods, mostly in
NSCLC and mPCa. As a consequence of these advan-
tages and in particular because the number of CTCs is
critical for assessing molecular biomarkers, filtration
based enrichment methods may be a preferred technique
to progress CTCs as a non-invasive approach for select-
ing specific therapies. Given this clinical perspective,
automation of microscopy analysis is a necessary step to
improve reproducibility of analyses, reduce risks of er-
rors, inter-operator differences, and progress towards a
standardization of filtration-enriched CTC analysis. Fur-
thermore, a second advantage of the automated analysis
of filtration-enriched CTC is the possibility to combine
successive assays on the same filter. Automation allows
precise location of cells on filters, thus relocating cell
data and images from successive experiments performed
on the same filter. The combination of assays increases
the amount of available information, contributing to a
better characterization of CTCs and reliability of the
results.
Table 4 FISH spots detected per CTC in a patient with an
ALK-rearranged tumor depending on the step
CTC ID Number of FA-FISH spots
0.5 μm 0.6 μm 0.7 μm 0.8 μm
1 16 16 16 16
2 16 16 16 16
3 32 32 32 28
4 32 32 28 27
5 16 16 14 13
6 32 32 32 32
7 14 14 14 14
8 13 16 12 16
9 29 28 32 32
10 16 16 16 16
11 16 16 16 16
12 28 26 31 30
13 32 32 32 30
14 32 32 32 32
15 14 14 14 14
16 27 28 18 27
17 16 16 16 16
18 14 14 14 12
19 30 32 30 27
20 16 16 16 14
21 16 16 16 16
22 32 32 31 22
23 32 32 32 27
24 32 32 32 32
%a 79 % 92 % 75 % 58 %
Abbreviations: ALK anaplastic lymphoma kinase gene; CTC, circulating tumor
cell; FISH, fluorescence in situ hybridization
aPercentage of cases where a higher number of FISH spots were observed
The numbers in bold correspond to the highest number of spots for this CTC
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Fig. 4 (See legend on next page.)
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(See figure on previous page.)
Fig. 4 Detection of ALK-rearrangement and gain of ALK-native copies in CTCs from a patient with an ALK-rearranged tumor using the multi-exposure
protocol. ALK-gene status was tested in filtration enriched-CTCs by combined fluorescent staining and fluorescent in situ hybridization (FISH).
FISH signals were captured with the multi-exposure protocol and 9 out of the 27 possibilities are shown. Images of best exposure level for
red and green signals are framed in yellow. a Detection ALK-rearrangement. Green and red arrows indicate the break apart signal. b Detection
of gain of ALK-native copies. Scale: white bars = 10 μm
Fig. 5 Examples of gene-rearrangement detection in filtration enriched-CTCs from NSCLC and mPCa patients by combined fluorescent staining
and fluorescent in situ hybridization (FISH). a Example of ALK-rearrangement detection in NSCLC patients with an ALK-rearranged tumor. b Example of
ROS1-rearrangement detection in NSCLC patients with a ROS1-rearranged tumor. c Example of RET-rearrangement detection in NSCLC patients with a
RET-rearranged tumor. d Example of ERG-rearrangement detection in mPCa patients with an ERG-rearranged tumor. Gene rearrangements are shown
by green and red. Scale: white bars = 10 μm
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Conclusions
While offering important advantages such as sensitivity
of CTC capture and flexibility for CTC characterization,
filtration systems have disadvantages that make the auto-
mation of microscopy challenging to implement. Manual
analysis of filtration-enriched CTCs is time-consuming
and highly operator-dependent for large scale analyzes
and clinical validation of CTC filtration assays. Here we
report a semi-automated microscopy method established
to identify filtration-enriched CTCs from NSCLC and
mPCa, and detect molecular biomarkers such as ALK-,
ROS1- and ERG-rearrangements in CTCs. This method
may help to improve reproducibility, reduce inter-
operator difference and duration of filtration-enriched
CTC assays. In addition, data issued from successive ex-
periments may be gathered, further improving and refin-
ing CTC characterization. By increasing the feasibility
and reliability of filtration-enriched CTC assays, the
present method may be helpful to progress towards their
standardization and validation. This will contribute to
advancing these assays towards the clinic using a routine
clinical test.
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